We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00167869
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : May 29, 2008
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:
Hypertension is an increasingly important medical and public health issue. Literature suggests that there may be a role for dairy foods in the prevention and treatment of hypertension. Recently, it has been suggested that several peptides in milk proteins could have blood pressure lowering properties. LACTOPRES is a randomised, double-blind parallel trial to assess the blood pressure effect of an increased intake of dairy peptides in humans.

Condition or disease Intervention/treatment Phase
Hypertension Behavioral: dairy peptides Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 135 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.
Study Start Date : June 2004
Primary Completion Date : June 2005
Study Completion Date : June 2005
Arms and Interventions


Outcome Measures

Primary Outcome Measures :
  1. Blood pressure

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • systolic blood pressure >= 140 mmHg
  • BMI between 18 and 32 kg/m2
  • apparently healthy

Exclusion Criteria:

  • antihypertensive medication
  • medically prescribed or slimming diet
  • lactating, pregnant
  • irregular pulse
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00167869


Locations
Netherlands
Wageningen University, Division of Human Nutrition
Wageningen, Netherlands, 6700 EV
Sponsors and Collaborators
Wageningen University
Unilever R&D
Investigators
Principal Investigator: Frans J Kok, PhD Wageningen University - Division of Human Nutrition
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00167869     History of Changes
Other Study ID Numbers: METC-WU 04/04
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: May 29, 2008
Last Verified: May 2008

Keywords provided by Wageningen University:
hypertension
blood pressure
dairy peptides
bioactive peptides
randomized controlled trial

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases